Since depletion of Caveolin-1 leads to a reduction of SMAD1/5, Caveolin-1, rather than ALK1 or BMP9, could be an interesting target for the treatment of vascular diseases, especially in early atherosclerosis [75]. This evidence concerns the gene CAV1 and atherosclerosis.